WealthPlan Investment Management’s Xtrackers USD High Yield Corporate Bond ETF HYLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.31M Buy
118,148
+22,834
+24% +$834K 0.21% 94
2026
Q1
$3.45M Buy
95,314
+22,361
+31% +$822K 0.19% 115
2025
Q4
$2.69M Buy
72,953
+16,878
+30% +$622K 0.17% 113
2025
Q3
$2.08M Buy
56,075
+41,865
+295% +$1.54M 0.14% 127
2025
Q2
$525K Sell
14,210
-78
-0.5% -$2.81K 0.04% 233
2025
Q1
$517K Sell
14,288
-1,144
-7% -$41.6K 0.05% 168
2024
Q4
$557K Buy
+15,432
New +$563K 0.06% 160
2023
Q1
– Sell
-17,560
Closed -$602K – 490
2022
Q4
$602K Buy
17,560
+18
+0.1% +$608 0.04% 232
2022
Q3
$602K Buy
+17,542
New +$607K 0.04% 217
2022
Q1
$637K Buy
+17,727
New +$679K 0.04% 222

Other funds holding HYLB

WealthPlan Investment Management's HYLB Position: Q2 2026 in Review

WealthPlan Investment Management increased its Xtrackers USD High Yield Corporate Bond ETF (HYLB) stake by 24% in Q2 2026, buying an estimated $834K and bringing the position to 118,148 shares worth $4.31M. The position accounts for 0.21% of the portfolio, ranked #94.

WealthPlan Investment Management first reported a position in HYLB in Q1 2022 and has held it in 10 quarters since. 239 funds tracked by Wall St. Rank hold HYLB as of Q2 2026.

  • WealthPlan Investment Management held 118,148 shares of Xtrackers USD High Yield Corporate Bond ETF worth $4.31M as of Q2 2026.
  • WealthPlan Investment Management bought 22,834 Xtrackers USD High Yield Corporate Bond ETF shares in Q2 2026, an estimated $834K.
  • Xtrackers USD High Yield Corporate Bond ETF made up 0.21% of WealthPlan Investment Management's portfolio in Q2 2026, its #94 holding.
  • WealthPlan Investment Management first reported a position in Xtrackers USD High Yield Corporate Bond ETF in Q1 2022 and has held it in 10 quarters since.
  • 239 funds tracked by Wall St. Rank held Xtrackers USD High Yield Corporate Bond ETF as of Q2 2026.

Based on WealthPlan Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.